摘要
目的探讨早期应用干扰素与人免疫球蛋白联合对重症手足口病治疗效果及对T淋巴细胞亚群水平的改善价值。方法选取2018年6月至2020年6月收治的手足口病患儿100例,随机数字表分为对照组和观察组,每组50例。对照组给予干扰素雾化吸入治疗,观察组给予干扰素+人免疫球蛋白治疗,观察2组临床疗效、患儿症状改善时间、炎性因子[白介素-2(IL-2)、IL-6、肿瘤坏死因子-α(TNF-α)]及T淋巴细胞亚群变化情况。结果观察组临床总疗效为94.00%高于对照组的70.00%(P<0.05);观察组住院时间、血压恢复正常、心率恢复正常及末梢循环改善时间短于对照组(P<0.05);观察组IL-2、IL-6、IL-10及TNF-α水平低于对照组(P<0.05);观察组CD3^(+)、CD4^(+)、CD8^(+)以及CD4^(+)/CD8^(+)水平均优于对照组(P<0.05)。结论重症手足口病患儿临床治疗中选用人免疫球蛋白、干扰素联合方案,可有效降低患儿炎性反应,提高患儿T淋巴细胞亚群水平,提升免疫功能改善效果,促进患儿恢复速度,获得更理想的治疗有效性。
Objective To explore the efficacy of an early application of human immunoglobulin combined with interferon on T lymphocyte subsets levels in children with severe hand-foot-mouth disease(HFMD).Methods A total of 100 children with severe HFMD admitted from June 2018 to June 2020 were enrolled.They were divided into the control group(50 cases)and observation group(50 cases)based on disease severity.Children in both groups were treated with inhaled nebulised interferon,and those in the observation group were additionally given human immunoglobulin.The clinical efficacy,time of symptom improvement,inflammatory factor,and T lymphocyte subsets levels were compared.Results After treatment,the total clinical efficacy of the observation group was significantly higher than that of control group(94.00%vs 70.00%,P<0.05).Length of stay,time to blood pressure recovery and heart rate recovery,time to peripheral circulation improvement in the observation group were significantly shorter than those of control group(P<0.05).The interleukin 2(IL-2),IL-6,IL-10 and tumour necrosis factor alpha(TNF-α)levels in the observation group were significantly lower than those of the control group(P<0.05),and the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in the observation group were significantly better than those of the control group(P<0.05).Conclusion Human immunoglobulin combined with interferon effectively alleviate inflammatory response,enhance T lymphocyte subsets,improve immune function and accelerate the recovery of children with severe HFMD.
作者
刘召璞
刘丽敏
王云茹
郝现伟
LIU Zhaopu;LIU Limin;WANG Yunru(Department of Pediatrics,Xingtai Central Hospital,Hebei,Xingtai 054000,China)
出处
《河北医药》
CAS
2024年第9期1353-1356,共4页
Hebei Medical Journal
基金
邢台市重点研发计划自筹项目(编号:2022ZC202)。
关键词
重症
手足口病
人免疫球蛋白
干扰素
T淋巴细胞亚群水平
炎性因子
severe hand-foot-mouth disease
human immunoglobulin
interferon
T lymphocyte subsets
inflammatory factors
